Go to Contents Go to Navigation

Samsung Bioepis seeks to develop generic drug for macular degeneration

All Headlines 10:20 June 04, 2017

SEOUL, June 4 (Yonhap) -- Samsung Bioepis Co. is seeking to develop a biosimilar version of a drug for macular degeneration, a visual disorder, industry sources said Sunday.

According to sources, Samsung Bioepis recently announced a plan to test a biosimilar of Lucentis, which was developed by global pharmaceutical players Genentech and Novartis to treat macular degeneration. The drug posted sales of US$3.8 billion around the globe as of 2015.

A biosimilar is a copied medicine developed after patents for the original drug have expired.

Macular degeneration is considered to be one of the major diseases that leads to a loss of vision for seniors.

Samsung Bioepis is set to conduct tests by comparing the original drug with its biosimilar. The test is set to start in September this year.

An official from Samsung Bioepis, however, said the company cannot yet determine when it will release the biosimilar, as there are different expiration dates of the patent rights to Lucentis in different countries.

Samsung Bioepis seeks to develop generic drug for macular degeneration - 1

colin@yna.co.kr
(END)

HOME TOP
Send Feedback
How can we improve?
Thanks for your feedback!